Symptomatic osteonecrosis in French survivors of childhood and adolescent leukemia: a clinical and MRI study of LEA cohort

Huault, Alice; Gautier, Michel; Charon, Valérie; Chouklati, Kamal; Domenech, Carine; Chastagner, Pascal; Dalle, Jean‐Hugues; Paillard, Catherine; Ducassou, Stéphane; Poirée, Marilyne; Plat, Geneviève; Tabone, Marie‐Dominique; Kanold, Justyna; Baruchel, André; Berger, Claire; Pellier, Isabelle; Plantaz, Dominique; Théron, Alexandre; Mustafa, Alaa; Auquier, Pascal; Gandemer, Virginie

doi:10.1080/08880018.2023.2168810

Pediatric Hematology and Oncology

2023

DOI: 10.1080/08880018.2023.2168810

|View full text |Cite

Symptomatic osteonecrosis in French survivors of childhood and adolescent leukemia: a clinical and MRI study of LEA cohort

Alice Huault

Michel Gautier

Valérie Charon

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

How I treat long-term survivors of childhood acute leukemia

Saultier,

Michel

2024

Blood

View full text Add to dashboard Cite

The population of childhood leukemia survivors who reach adulthood is growing due to improved therapy. However, survivors are at risk of long-term complications. Comprehensive follow-up programs play a key role in childhood leukemia survivor care. The major determinant of long-term complications is the therapeutic burden accumulated over time. Relapse chemotherapy, central nervous system irradiation, hematopoietic stem cell transplantation and total body irradiation are associated with greater risk of long-term complications. Other parameters include clinical characteristics such as age and sex as well as environmental, genetic and socio-economic factors, which can help to stratify the risk of long-term complications and organize the follow-up program. Early diagnosis improves the management of several late complications such as anthracycline-related cardiomyopathy, secondary cancers, metabolic syndrome, development defects and infertility. Total body irradiation is the treatment associated with the worse long-term toxicity profile with a wide range of complications. Patients treated with chemotherapy alone are at a lower risk of long-term complications, although the optimal long-term follow-up remains unclear. Novel immunotherapies and targeted therapy are generally associated with a better short-term safety profile but still require careful long-term toxicity monitoring. Advances in understanding genetic susceptibility to long-term complications could enable tailored therapeutic strategies for leukemia treatment and optimized follow-up programs.

show abstract

How I treat long-term survivors of childhood acute leukemia

Saultier,

Michel

2024

Blood

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Symptomatic osteonecrosis in French survivors of childhood and adolescent leukemia: a clinical and MRI study of LEA cohort

Cited by 1 publication

References 40 publications

How I treat long-term survivors of childhood acute leukemia

How I treat long-term survivors of childhood acute leukemia

Contact Info

Product

Resources

About